Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA could use more appropriations, von Eschenbach tells Senate

This article was originally published in The Gray Sheet

Executive Summary

FDA could easily absorb an additional $100 million in funding over that proposed by the Bush Administration for fiscal 2009, but not the full $375 million increase recommended by the FDA Science Board in February, Commissioner Andrew von Eschenbach tells the Senate Appropriations Committee at an April 15 hearing. "I do believe we could absorb [$100 million] quite rapidly and ... effectively," but above that level "it would require greater stewardship to be sure we could implement those dollars as rapidly and effectively as we need to," he said. The administration's proposal provides a $51 million increase over 2008 in direct appropriations to FDA, bringing U.S. treasury funding of the agency to $1.77 billion (1"The Gray Sheet" March 3, 2008, p. 13)

You may also be interested in...



Funding Advice From FDA Science Board: Double Total Over Next Five Budgets

FDA Science Board members recommend a nearly $1.9 billion direct appropriation for the agency in fiscal 2009, a $375 million increase over 2008, and larger increases in each of the following five federal budgets

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel